BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 25281505)

  • 1. Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia.
    Bentley VL; Veinotte CJ; Corkery DP; Pinder JB; LeBlanc MA; Bedard K; Weng AP; Berman JN; Dellaire G
    Haematologica; 2015 Jan; 100(1):70-6. PubMed ID: 25281505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
    Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
    Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.
    Zuurbier L; Petricoin EF; Vuerhard MJ; Calvert V; Kooi C; Buijs-Gladdines JG; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Pieters R; Meijerink JP
    Haematologica; 2012 Sep; 97(9):1405-13. PubMed ID: 22491738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
    Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
    Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
    Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
    Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
    De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
    Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
    Gutierrez A; Sanda T; Grebliunaite R; Carracedo A; Salmena L; Ahn Y; Dahlberg S; Neuberg D; Moreau LA; Winter SS; Larson R; Zhang J; Protopopov A; Chin L; Pandolfi PP; Silverman LB; Hunger SP; Sallan SE; Look AT
    Blood; 2009 Jul; 114(3):647-50. PubMed ID: 19458356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
    Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
    Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
    Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
    Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
    Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
    Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
    Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP
    Blood; 2010 Feb; 115(6):1175-84. PubMed ID: 20008304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
    Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
    J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
    Dail M; Li Q; McDaniel A; Wong J; Akagi K; Huang B; Kang HC; Kogan SC; Shokat K; Wolff L; Braun BS; Shannon K
    Proc Natl Acad Sci U S A; 2010 Mar; 107(11):5106-11. PubMed ID: 20194733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
    Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
    Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
    Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
    Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
    Knoechel B; Roderick JE; Williamson KE; Zhu J; Lohr JG; Cotton MJ; Gillespie SM; Fernandez D; Ku M; Wang H; Piccioni F; Silver SJ; Jain M; Pearson D; Kluk MJ; Ott CJ; Shultz LD; Brehm MA; Greiner DL; Gutierrez A; Stegmaier K; Kung AL; Root DE; Bradner JE; Aster JC; Kelliher MA; Bernstein BE
    Nat Genet; 2014 Apr; 46(4):364-70. PubMed ID: 24584072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.
    Bandapalli OR; Zimmermann M; Kox C; Stanulla M; Schrappe M; Ludwig WD; Koehler R; Muckenthaler MU; Kulozik AE
    Haematologica; 2013 Jun; 98(6):928-36. PubMed ID: 23349303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.
    Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP
    PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Larson Gedman A; Chen Q; Kugel Desmoulin S; Ge Y; LaFiura K; Haska CL; Cherian C; Devidas M; Linda SB; Taub JW; Matherly LH
    Leukemia; 2009 Aug; 23(8):1417-25. PubMed ID: 19340001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.